{"id":"W2560046425","doi":"10.1182/blood.v114.22.3286.3286","title":"Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -;Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Nilotinib; Medicine; Imatinib; Internal medicine; Imatinib mesylate; Myeloid leukemia; Tyrosine-kinase inhibitor; Cancer","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003703439,0.0005423823,0.003214674,0.0009510327,0.00006690881,0.00003729525,0.0004922816,0.0002420456,0.00009666901],"category_scores_gemma":[0.001764632,0.0003317137,0.0003949287,0.002896065,0.0002100816,0.0002108849,0.0001548788,0.0007660214,0.00000120519],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00256536,"about_ca_system_score_gemma":0.003137653,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001179957,"about_ca_topic_score_gemma":0.01118047,"domain_scores_codex":[0.9923187,0.001327333,0.003886144,0.0009299265,0.0008623472,0.0006755296],"domain_scores_gemma":[0.9953392,0.001797221,0.00147929,0.001062927,0.0001275762,0.0001938485],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.03041336,0.02341517,0.8797187,0.0003649383,0.003341271,0.0002222479,0.002378762,0.0008031233,0.005078475,0.00001121788,0.000007200008,0.05424549],"study_design_scores_gemma":[0.190656,0.01006666,0.790042,0.001338365,0.003709698,0.000005249831,0.00017888,0.0008209613,0.002904668,0.000005358784,0.000008051151,0.0002641779],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9942434,0.0007481588,0.000008684246,0.00007842331,0.00005969844,0.004682436,0.00007752381,0.00002541001,0.0000762781],"genre_scores_gemma":[0.9992914,0.0002971494,0.00007896045,0.0000392425,0.00007565061,0.00008374047,0.00007159375,0.00004377147,0.00001847011],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1602426,"threshold_uncertainty_score":0.9999135,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05427079988921533,"score_gpt":0.3957849007024577,"score_spread":0.3415141008132423,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}